ID   NDKB_HUMAN              Reviewed;         152 AA.
AC   P22392; A8MWA3; Q1WM23; Q6LCT6;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 1.
DT   28-JAN-2026, entry version 260.
DE   RecName: Full=Nucleoside diphosphate kinase B {ECO:0000303|PubMed:17157250};
DE            Short=NDP kinase B {ECO:0000303|PubMed:1851158};
DE            Short=NDPK B {ECO:0000303|PubMed:1851158};
DE            EC=2.7.4.6 {ECO:0000269|PubMed:11121025, ECO:0000269|PubMed:16313181, ECO:0000269|PubMed:1851158, ECO:0000269|PubMed:25679041};
DE   AltName: Full=C-myc purine-binding transcription factor PUF {ECO:0000303|PubMed:8392752};
DE   AltName: Full=Histidine protein kinase NDKB;
DE            EC=2.7.13.3 {ECO:0000269|PubMed:17157250, ECO:0000269|PubMed:20946858};
DE   AltName: Full=Nucleoside diphoshate kinase 2 {ECO:0000303|PubMed:16313181};
DE            Short=NDK2 {ECO:0000303|PubMed:16313181};
DE   AltName: Full=nm23-H2 {ECO:0000303|PubMed:1988104};
GN   Name=NME2 {ECO:0000312|HGNC:HGNC:7850};
GN   Synonyms=NDK2 {ECO:0000303|PubMed:16313181}, NM23B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1988104;
RA   Stahl J.A., Leone A., Rosengard A.M., Porter L., Liotta L.A., Steeg P.S.,
RA   King C.R.;
RT   "Identification of a second human nm23 gene, nm23-H2.";
RL   Cancer Res. 51:445-449(1991).
RN   [2]
RP   PROTEIN SEQUENCE (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   BIOPHYSICOCHEMICAL PROPERTIES, SUBUNIT, AND ACTIVE SITE.
RX   PubMed=1851158; DOI=10.1016/s0021-9258(18)31515-1;
RA   Gilles A.-M., Presecan E., Vonica A., Lascu I.;
RT   "Nucleoside diphosphate kinase from human erythrocytes. Structural
RT   characterization of the two polypeptide chains responsible for
RT   heterogeneity of the hexameric enzyme.";
RL   J. Biol. Chem. 266:8784-8789(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=8392752; DOI=10.1126/science.8392752;
RA   Postel E.H., Berberich S.J., Flint S.J., Ferrone C.A.;
RT   "Human c-myc transcription factor PuF identified as nm23-H2 nucleoside
RT   diphosphate kinase, a candidate suppressor of tumor metastasis.";
RL   Science 261:478-480(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Neuroblastoma;
RX   PubMed=16442775; DOI=10.1016/j.ygeno.2005.11.004;
RA   Valentijn L.J., Koster J., Versteeg R.;
RT   "Read-through transcript from NM23-H1 into the neighboring NM23-H2 gene
RT   encodes a novel protein, NM23-LV.";
RL   Genomics 87:483-489(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-18.
RX   PubMed=7488060; DOI=10.1006/bbrc.1995.2550;
RA   Seifert M., Seib T., Engel M., Dooley S., Welter C.;
RT   "Characterization of the human nm23-H2 promoter region and localization of
RT   the microsatellite D17S396.";
RL   Biochem. Biophys. Res. Commun. 215:910-914(1995).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, AND MUTAGENESIS OF THR-7 AND
RP   LYS-12.
RX   PubMed=9488696; DOI=10.1074/jbc.273.10.5662;
RA   Schaertl S., Konrad M., Geeves M.A.;
RT   "Substrate specificity of human nucleoside-diphosphate kinase revealed by
RT   transient kinetic analysis.";
RL   J. Biol. Chem. 273:5662-5669(1998).
RN   [9]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=11121025; DOI=10.1073/pnas.97.26.14194;
RA   Postel E.H., Abramczyk B.M., Levit M.N., Kyin S.;
RT   "Catalysis of DNA cleavage and nucleoside triphosphate synthesis by NM23-
RT   H2/NDP kinase share an active site that implies a DNA repair function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:14194-14199(2000).
RN   [10]
RP   FUNCTION.
RX   PubMed=11694515; DOI=10.1074/jbc.m108359200;
RA   Ma D., Xing Z., Liu B., Pedigo N.G., Zimmer S.G., Bai Z., Postel E.H.,
RA   Kaetzel D.M.;
RT   "NM23-H1 and NM23-H2 repress transcriptional activities of nuclease-
RT   hypersensitive elements in the platelet-derived growth factor-A promoter.";
RL   J. Biol. Chem. 277:1560-1567(2002).
RN   [11]
RP   INTERACTION WITH ITGB1BP1, AND SUBCELLULAR LOCATION.
RX   PubMed=11919189; DOI=10.1074/jbc.m200200200;
RA   Fournier H.N., Dupe-Manet S., Bouvard D., Lacombe M.L., Marie C.,
RA   Block M.R., Albiges-Rizo C.;
RT   "Integrin cytoplasmic domain-associated protein 1alpha (ICAP-1alpha)
RT   interacts directly with the metastasis suppressor nm23-H2, and both
RT   proteins are targeted to newly formed cell adhesion sites upon integrin
RT   engagement.";
RL   J. Biol. Chem. 277:20895-20902(2002).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH AKAP13.
RX   PubMed=15249197; DOI=10.1016/j.bbrc.2004.06.067;
RA   Iwashita S., Fujii M., Mukai H., Ono Y., Miyamoto M.;
RT   "Lbc proto-oncogene product binds to and could be negatively regulated by
RT   metastasis suppressor nm23-H2.";
RL   Biochem. Biophys. Res. Commun. 320:1063-1068(2004).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVE SITE, AND AUTOPHOSPHORYLATION.
RX   PubMed=16313181; DOI=10.1021/bi0515974;
RA   Yoon J.H., Singh P., Lee D.H., Qiu J., Cai S., O'Connor T.R., Chen Y.,
RA   Shen B., Pfeifer G.P.;
RT   "Characterization of the 3' --> 5' exonuclease activity found in human
RT   nucleoside diphosphate kinase 1 (NDK1) and several of its homologues.";
RL   Biochemistry 44:15774-15786(2005).
RN   [14]
RP   FUNCTION AS HISTIDINE PROTEIN KINASE, CATALYTIC ACTIVITY, AND MUTAGENESIS
RP   OF HIS-118.
RX   PubMed=17157250; DOI=10.1016/j.molcel.2006.11.012;
RA   Srivastava S., Li Z., Ko K., Choudhury P., Albaqumi M., Johnson A.K.,
RA   Yan Y., Backer J.M., Unutmaz D., Coetzee W.A., Skolnik E.Y.;
RT   "Histidine phosphorylation of the potassium channel KCa3.1 by nucleoside
RT   diphosphate kinase B is required for activation of KCa3.1 and CD4 T
RT   cells.";
RL   Mol. Cell 24:665-675(2006).
RN   [15]
RP   INTERACTION WITH BCL2L10, AND SUBCELLULAR LOCATION.
RX   PubMed=17532299; DOI=10.1016/j.bbrc.2007.05.090;
RA   Kang Y., Lee D.C., Han J., Yoon S., Won M., Yeom J.H., Seong M.J., Ko J.J.,
RA   Lee K.A., Lee K., Bae J.;
RT   "NM23-H2 involves in negative regulation of Diva and Bcl2L10 in apoptosis
RT   signaling.";
RL   Biochem. Biophys. Res. Commun. 359:76-82(2007).
RN   [16]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19033359; DOI=10.1093/nar/gkn919;
RA   Thakur R.K., Kumar P., Halder K., Verma A., Kar A., Parent J.L.,
RA   Basundra R., Kumar A., Chowdhury S.;
RT   "Metastases suppressor NM23-H2 interaction with G-quadruplex DNA within c-
RT   MYC promoter nuclease hypersensitive element induces c-MYC expression.";
RL   Nucleic Acids Res. 37:172-183(2009).
RN   [17]
RP   FUNCTION AS HISTIDINE PROTEIN KINASE.
RX   PubMed=20946858; DOI=10.1016/s0076-6879(10)71020-x;
RA   Wieland T., Hippe H.J., Ludwig K., Zhou X.B., Korth M., Klumpp S.;
RT   "Reversible histidine phosphorylation in mammalian cells: a teeter-totter
RT   formed by nucleoside diphosphate kinase and protein histidine phosphatase
RT   1.";
RL   Methods Enzymol. 471:379-402(2010).
RN   [18]
RP   FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=25679041; DOI=10.1021/bi501284g;
RA   Kopylov M., Bass H.W., Stroupe M.E.;
RT   "The maize (Zea mays L.) nucleoside diphosphate kinase1 (ZmNDPK1) gene
RT   encodes a human NM23-H2 homologue that binds and stabilizes G-quadruplex
RT   DNA.";
RL   Biochemistry 54:1743-1757(2015).
RN   [19] {ECO:0007744|PDB:1NSK}
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS), AND SUBUNIT.
RX   PubMed=7658474; DOI=10.1006/jmbi.1995.0457;
RA   Webb P.A., Perisic O., Mendola C.E., Backer J.M., Williams R.L.;
RT   "The crystal structure of a human nucleoside diphosphate kinase, NM23-H2.";
RL   J. Mol. Biol. 251:574-587(1995).
RN   [20] {ECO:0007744|PDB:1NUE}
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 2-152 IN COMPLEX WITH GDP AND
RP   MG(2+), COFACTOR, AND SUBUNIT.
RX   PubMed=8747457; DOI=10.1016/s0969-2126(01)00268-4;
RA   Morera S., Lacombe M.-L., Xu Y., Lebras G., Janin J.;
RT   "X-ray structure of human nucleoside diphosphate kinase B complexed with
RT   GDP at 2-A resolution.";
RL   Structure 3:1307-1314(1995).
RN   [21] {ECO:0007744|PDB:3BBB, ECO:0007744|PDB:3BBC, ECO:0007744|PDB:3BBF}
RP   X-RAY CRYSTALLOGRAPHY (1.30 ANGSTROMS) OF 2-152 IN COMPLEX WITH GDP; MG(2+)
RP   AND DNA AND OF 2-152 OF MUTANT ALA-88, FUNCTION, COFACTOR, SUBUNIT,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF ARG-88.
RX   PubMed=19435876; DOI=10.1158/1535-7163.mct-08-1093;
RA   Dexheimer T.S., Carey S.S., Zuohe S., Gokhale V.M., Hu X., Murata L.B.,
RA   Maes E.M., Weichsel A., Sun D., Meuillet E.J., Montfort W.R., Hurley L.H.;
RT   "NM23-H2 may play an indirect role in transcriptional activation of c-myc
RT   gene expression but does not cleave the nuclease hypersensitive element
RT   III(1).";
RL   Mol. Cancer Ther. 8:1363-1377(2009).
RN   [22] {ECO:0007744|PDB:8PIE}
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 2-152, AND ACTIVATION OF
RP   ANTIVIRAL BEMNIFOSBUVIR.
RX   PubMed=39190717; DOI=10.1371/journal.pbio.3002743;
RA   Chazot A., Zimberger C., Feracci M., Moussa A., Good S., Sommadossi J.P.,
RA   Alvarez K., Ferron F., Canard B.;
RT   "The activation cascade of the broad-spectrum antiviral bemnifosbuvir
RT   characterized at atomic resolution.";
RL   PLoS Biol. 22:e3002743-e3002743(2024).
CC   -!- FUNCTION: Catalyzes the transfer of a gamma-phosphoryl group from a
CC       nucleoside triphosphate, mainly ATP, to a nucleoside diphosphate via a
CC       ping-pong mechanism involving a phosphohistidine intermediate,
CC       therefore contributing to the nucleoside triphosphate homeostasis
CC       (PubMed:11121025, PubMed:16313181, PubMed:1851158, PubMed:25679041).
CC       Also functions as a histidine protein kinase by transferring the
CC       phosphoryl group from the phosphohistidine intermediate to a histidine
CC       residue in target proteins (PubMed:17157250, PubMed:20946858).
CC       Phosphorylates the GNB1 subunit of heterotrimeric G proteins at 'His-
CC       266', generating a high-energy phosphate group that promotes GTP
CC       formation and enables receptor-independent activation of heterotrimeric
CC       G proteins (By similarity). Also phosphorylates KCNN4 at 'His-358',
CC       leading to activation of its intermediate conductance calcium-activated
CC       potassium channel activity, Ca(2+) influx, and subsequent activation of
CC       B and T cells (PubMed:17157250). Additionally involved in
CC       transcriptional regulation through direct DNA binding and chromatin
CC       remodeling (PubMed:11121025, PubMed:11694515, PubMed:19033359,
CC       PubMed:19435876, PubMed:25679041, PubMed:8392752). In this context,
CC       functions as a single-stranded DNA binding protein that binds and
CC       stabilizes the G-quadruplex (G4) structures within the nuclease
CC       hypersensitive element (NHE) III(1) region of the MYC gene promoter,
CC       facilitating recruitment of additional single-strand DNA binding
CC       proteins and activation of MYC transcription (PubMed:19033359,
CC       PubMed:19435876, PubMed:25679041, PubMed:8392752). G4 DNA-binding
CC       activity is independent of its nucleoside diphosphate kinase function
CC       and recognizes both folded and unfolded G4 structures
CC       (PubMed:25679041). With NME1, may regulate acetyl-CoA (AcCoA) usage
CC       between histone acetylation and fatty acid synthesis by targeting AcCoA
CC       release at ATP-rich, HAT-associated chromatin regions (By similarity).
CC       Also negatively regulates Rho activity by interacting with AKAP13/LBC
CC       (PubMed:15249197). {ECO:0000250|UniProtKB:Q01768,
CC       ECO:0000250|UniProtKB:Q3T0Q4, ECO:0000269|PubMed:11121025,
CC       ECO:0000269|PubMed:11694515, ECO:0000269|PubMed:15249197,
CC       ECO:0000269|PubMed:16313181, ECO:0000269|PubMed:17157250,
CC       ECO:0000269|PubMed:1851158, ECO:0000269|PubMed:19033359,
CC       ECO:0000269|PubMed:19435876, ECO:0000269|PubMed:20946858,
CC       ECO:0000269|PubMed:25679041, ECO:0000269|PubMed:8392752}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 2'-deoxyribonucleoside 5'-diphosphate + ATP = a 2'-
CC         deoxyribonucleoside 5'-triphosphate + ADP; Xref=Rhea:RHEA:44640,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61560, ChEBI:CHEBI:73316,
CC         ChEBI:CHEBI:456216; EC=2.7.4.6;
CC         Evidence={ECO:0000269|PubMed:11121025, ECO:0000269|PubMed:16313181,
CC         ECO:0000269|PubMed:25679041};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:44641;
CC         Evidence={ECO:0000269|PubMed:11121025, ECO:0000269|PubMed:16313181,
CC         ECO:0000269|PubMed:25679041};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a ribonucleoside 5'-diphosphate + ATP = a ribonucleoside 5'-
CC         triphosphate + ADP; Xref=Rhea:RHEA:18113, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:57930, ChEBI:CHEBI:61557, ChEBI:CHEBI:456216; EC=2.7.4.6;
CC         Evidence={ECO:0000269|PubMed:1851158};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18114;
CC         Evidence={ECO:0000269|PubMed:1851158};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=IDP + ATP = ITP + ADP; Xref=Rhea:RHEA:30347,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:58280, ChEBI:CHEBI:61402,
CC         ChEBI:CHEBI:456216; EC=2.7.4.6;
CC         Evidence={ECO:0000269|PubMed:1851158};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:30348;
CC         Evidence={ECO:0000269|PubMed:1851158};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=GDP + ATP = GTP + ADP; Xref=Rhea:RHEA:27686,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:37565, ChEBI:CHEBI:58189,
CC         ChEBI:CHEBI:456216; EC=2.7.4.6;
CC         Evidence={ECO:0000250|UniProtKB:Q01768};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:27687;
CC         Evidence={ECO:0000250|UniProtKB:Q01768};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ADP + ATP = ADP + ATP; Xref=Rhea:RHEA:84315,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000250|UniProtKB:P19804};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:84316;
CC         Evidence={ECO:0000250|UniProtKB:P19804};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=UDP + ATP = UTP + ADP; Xref=Rhea:RHEA:25098,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:46398, ChEBI:CHEBI:58223,
CC         ChEBI:CHEBI:456216; EC=2.7.4.6;
CC         Evidence={ECO:0000250|UniProtKB:P19804};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25099;
CC         Evidence={ECO:0000250|UniProtKB:P19804};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=CDP + ATP = CTP + ADP; Xref=Rhea:RHEA:25237,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:37563, ChEBI:CHEBI:58069,
CC         ChEBI:CHEBI:456216; EC=2.7.4.6;
CC         Evidence={ECO:0000250|UniProtKB:P19804};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:25238;
CC         Evidence={ECO:0000250|UniProtKB:P19804};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=dTDP + ATP = dTTP + ADP; Xref=Rhea:RHEA:27682,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:37568, ChEBI:CHEBI:58369,
CC         ChEBI:CHEBI:456216; EC=2.7.4.6;
CC         Evidence={ECO:0000269|PubMed:11121025, ECO:0000269|PubMed:16313181,
CC         ECO:0000269|PubMed:25679041};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:27683;
CC         Evidence={ECO:0000269|PubMed:11121025, ECO:0000269|PubMed:16313181,
CC         ECO:0000269|PubMed:25679041};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + protein L-histidine = ADP + protein N-phospho-L-
CC         histidine.; EC=2.7.13.3; Evidence={ECO:0000269|PubMed:17157250,
CC         ECO:0000269|PubMed:20946858};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:19435876, ECO:0000269|PubMed:8747457};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=60 uM for IDP {ECO:0000269|PubMed:1851158};
CC   -!- SUBUNIT: Homohexamer (PubMed:1851158, PubMed:19435876, PubMed:7658474,
CC       PubMed:8747457). Heterohexamer of two different chains: A/NME1 and
CC       B/NME2 (A5B or A4B2 or A3B3 or A2B4 or AB5) (PubMed:1851158). Interacts
CC       with CAPN8 (By similarity). Interacts with AKAP13 (PubMed:15249197).
CC       Interacts with ITGB1BP1 (via C-terminal domain region); this
CC       interaction leads to their recruitment to ITGB1-rich cell adhesion
CC       sites in cell spreading on FN1 (PubMed:11919189). Interacts with
CC       BCL2L10 (PubMed:17532299). {ECO:0000250|UniProtKB:Q01768,
CC       ECO:0000269|PubMed:11919189, ECO:0000269|PubMed:15249197,
CC       ECO:0000269|PubMed:17532299, ECO:0000269|PubMed:1851158,
CC       ECO:0000269|PubMed:19435876, ECO:0000269|PubMed:7658474,
CC       ECO:0000269|PubMed:8747457}.
CC   -!- INTERACTION:
CC       P22392; P50570: DNM2; NbExp=2; IntAct=EBI-713693, EBI-346547;
CC       P22392; O14713-1: ITGB1BP1; NbExp=7; IntAct=EBI-713693, EBI-2127367;
CC       P22392; P15531: NME1; NbExp=7; IntAct=EBI-713693, EBI-741141;
CC       P22392; P22392: NME2; NbExp=3; IntAct=EBI-713693, EBI-713693;
CC       P22392; Q13232: NME3; NbExp=4; IntAct=EBI-713693, EBI-713684;
CC       P22392; O00746: NME4; NbExp=6; IntAct=EBI-713693, EBI-744871;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17532299}. Nucleus
CC       {ECO:0000305|PubMed:19033359, ECO:0000305|PubMed:19435876,
CC       ECO:0000305|PubMed:25679041, ECO:0000305|PubMed:8392752}. Cell
CC       projection, lamellipodium {ECO:0000269|PubMed:11919189}. Cell
CC       projection, ruffle {ECO:0000269|PubMed:11919189}. Note=Colocalizes with
CC       ITGB1 and ITGB1BP1 at the edge or peripheral ruffles and lamellipodia
CC       during the early stages of cell spreading on fibronectin or collagen
CC       but not on vitronectin or laminin substrates.
CC       {ECO:0000269|PubMed:11919189}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasm
CC       {ECO:0000269|PubMed:16442775}. Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:16442775}. Nucleus {ECO:0000269|PubMed:16442775}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Cytoplasm
CC       {ECO:0000269|PubMed:16442775}. Cytoplasm, perinuclear region
CC       {ECO:0000269|PubMed:16442775}. Nucleus {ECO:0000269|PubMed:16442775}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=NM23-H2;
CC         IsoId=P22392-1; Sequence=Displayed;
CC       Name=3; Synonyms=NM23-LV;
CC         IsoId=P22392-2; Sequence=VSP_036708;
CC   -!- TISSUE SPECIFICITY: [Isoform 1]: Ubiquitously expressed.
CC       {ECO:0000269|PubMed:16442775}.
CC   -!- TISSUE SPECIFICITY: [Isoform 3]: Ubiquitously expressed.
CC       {ECO:0000269|PubMed:16442775}.
CC   -!- PTM: Autophosphorylated. {ECO:0000269|PubMed:16313181,
CC       ECO:0000269|PubMed:20946858}.
CC   -!- MISCELLANEOUS: Involved in the activation pathway of bemnifosbuvir (AT-
CC       527) and its epimer, AT-752 (PubMed:39190717). AT-527 and AT-752 are
CC       two guanosine analogs tested in clinical trials against several RNA
CC       viruses, which are activated into their common 5'-triphosphate AT-9010
CC       in human cells (PubMed:39190717). Mediates the last activation step by
CC       catalyzing transformation of AT-8500 into AT-9010 (PubMed:39190717).
CC       {ECO:0000269|PubMed:39190717}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Based on a naturally occurring readthrough
CC       transcript which produces an NME1-NME2 fusion protein.
CC       {ECO:0000269|PubMed:16442775}.
CC   -!- SIMILARITY: Belongs to the NDK family. {ECO:0000305}.
CC   -!- CAUTION: Originnally, in addition to its DNA binding activity, some
CC       reports shown that exhibited an intrinsic nuclease activity
CC       (PubMed:11121025, PubMed:11694515). Bound DNA within the nuclease
CC       hypersensitive element (NHE) III(1) region and cleaved the
CC       phosphodiester bond by transiently forming a covalent protein-DNA
CC       intermediate through a nucleophilic attack (PubMed:11121025). However,
CC       this nuclease activity has not been confirmed (PubMed:19435876).
CC       {ECO:0000269|PubMed:11121025, ECO:0000269|PubMed:11694515,
CC       ECO:0000269|PubMed:19435876}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X58965; CAB37870.1; -; mRNA.
DR   EMBL; M36981; AAA36369.1; -; mRNA.
DR   EMBL; L16785; AAA60228.1; -; mRNA.
DR   EMBL; DQ109675; AAZ82097.1; -; mRNA.
DR   EMBL; AC005839; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC002476; AAH02476.1; -; mRNA.
DR   EMBL; BC133029; AAI33030.1; -; mRNA.
DR   EMBL; BC133031; AAI33032.1; -; mRNA.
DR   EMBL; U29200; AAA86745.1; -; Genomic_DNA.
DR   CCDS; CCDS11580.1; -. [P22392-1]
DR   PIR; A49798; A49798.
DR   RefSeq; NP_001018146.1; NM_001018136.2. [P22392-2]
DR   RefSeq; NP_001018147.1; NM_001018137.3. [P22392-1]
DR   RefSeq; NP_001018148.1; NM_001018138.1. [P22392-1]
DR   RefSeq; NP_001018149.1; NM_001018139.2. [P22392-1]
DR   RefSeq; NP_002503.1; NM_002512.4. [P22392-1]
DR   PDB; 1NSK; X-ray; 2.80 A; L/N/O/R/T/U=1-152.
DR   PDB; 1NUE; X-ray; 2.00 A; A/B/C/D/E/F=2-152.
DR   PDB; 3BBB; X-ray; 1.30 A; A/B/C/D/E/F=2-152.
DR   PDB; 3BBC; X-ray; 1.70 A; A/B/C/D/E/F=2-152.
DR   PDB; 3BBF; X-ray; 1.70 A; A/B/C/D/E/F=2-152.
DR   PDB; 7KPF; X-ray; 2.23 A; A/B/C/D/E/F=1-152.
DR   PDB; 8PIE; X-ray; 1.90 A; A/B/C/D/E/F=2-152.
DR   PDB; 8PYW; X-ray; 1.55 A; A/B/C/D/E/F=2-152.
DR   PDBsum; 1NSK; -.
DR   PDBsum; 1NUE; -.
DR   PDBsum; 3BBB; -.
DR   PDBsum; 3BBC; -.
DR   PDBsum; 3BBF; -.
DR   PDBsum; 7KPF; -.
DR   PDBsum; 8PIE; -.
DR   PDBsum; 8PYW; -.
DR   AlphaFoldDB; P22392; -.
DR   SMR; P22392; -.
DR   BioGRID; 110895; 208.
DR   BioGRID; 576341; 97.
DR   DIP; DIP-50179N; -.
DR   FunCoup; P22392; 1873.
DR   IntAct; P22392; 141.
DR   MINT; P22392; -.
DR   STRING; 9606.ENSP00000376886; -.
DR   BindingDB; P22392; -.
DR   ChEMBL; CHEMBL2160; -.
DR   DrugBank; DB00787; Acyclovir.
DR   DrugBank; DB00718; Adefovir dipivoxil.
DR   DrugBank; DB00640; Adenosine.
DR   DrugBank; DB01262; Decitabine.
DR   DrugBank; DB04315; Guanosine-5'-Diphosphate.
DR   DrugBank; DB00709; Lamivudine.
DR   DrugBank; DB14126; Tenofovir.
DR   DrugBank; DB09299; Tenofovir alafenamide.
DR   DrugBank; DB00300; Tenofovir disoproxil.
DR   GlyGen; P22392; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P22392; -.
DR   MetOSite; P22392; -.
DR   PhosphoSitePlus; P22392; -.
DR   SwissPalm; P22392; -.
DR   BioMuta; NME2; -.
DR   DMDM; 127983; -.
DR   OGP; P22392; -.
DR   jPOST; P22392; -.
DR   MassIVE; P22392; -.
DR   PaxDb; 9606-ENSP00000376886; -.
DR   PeptideAtlas; P22392; -.
DR   PRIDE; P22392; -.
DR   ProteomicsDB; 53986; -. [P22392-1]
DR   ProteomicsDB; 53987; -. [P22392-2]
DR   Pumba; P22392; -.
DR   TopDownProteomics; P22392-1; -. [P22392-1]
DR   TopDownProteomics; P22392-2; -. [P22392-2]
DR   Antibodypedia; 35045; 416 antibodies from 26 providers.
DR   CPTC; P22392; 3 antibodies.
DR   DNASU; 4831; -.
DR   Ensembl; ENST00000393190.4; ENSP00000376886.1; ENSG00000243678.13. [P22392-1]
DR   Ensembl; ENST00000503064.5; ENSP00000426901.1; ENSG00000243678.13. [P22392-1]
DR   Ensembl; ENST00000512737.6; ENSP00000421064.1; ENSG00000243678.13. [P22392-1]
DR   Ensembl; ENST00000513177.5; ENSP00000425581.1; ENSG00000243678.13. [P22392-1]
DR   Ensembl; ENST00000514264.6; ENSP00000426976.2; ENSG00000243678.13. [P22392-1]
DR   GeneID; 4831; -.
DR   KEGG; hsa:4831; -.
DR   KEGG; hsa:654364; -.
DR   MANE-Select; ENST00000512737.6; ENSP00000421064.1; NM_002512.4; NP_002503.1.
DR   UCSC; uc002itj.4; human. [P22392-1]
DR   AGR; HGNC:33531; -.
DR   AGR; HGNC:7850; -.
DR   ClinPGx; PA162398077; -.
DR   CTD; 4831; -.
DR   DisGeNET; 4831; -.
DR   DisGeNET; 654364; -.
DR   GeneCards; NME2; -.
DR   HGNC; HGNC:7850; NME2.
DR   HPA; ENSG00000243678; Low tissue specificity.
DR   MIM; 156491; gene.
DR   OpenTargets; ENSG00000011052; -.
DR   OpenTargets; ENSG00000243678; -.
DR   VEuPathDB; HostDB:ENSG00000243678; -.
DR   eggNOG; KOG0888; Eukaryota.
DR   GeneTree; ENSGT00940000161569; -.
DR   HOGENOM; CLU_080881_1_0_1; -.
DR   InParanoid; P22392; -.
DR   OMA; GDFCIDL; -.
DR   OrthoDB; 2162449at2759; -.
DR   PAN-GO; P22392; 2 GO annotations based on evolutionary models.
DR   PhylomeDB; P22392; -.
DR   BioCyc; MetaCyc:HS04463-MONOMER; -.
DR   BRENDA; 2.7.4.6; 2681.
DR   PathwayCommons; P22392; -.
DR   Reactome; R-HSA-499943; Interconversion of nucleotide di- and triphosphates.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-9748787; Azathioprine ADME.
DR   Reactome; R-HSA-9755088; Ribavirin ADME.
DR   SignaLink; P22392; -.
DR   SIGNOR; P22392; -.
DR   Agora; ENSG00000243678; -.
DR   BioGRID-ORCS; 4831; 39 hits in 1156 CRISPR screens.
DR   BioGRID-ORCS; 654364; 20 hits in 1029 CRISPR screens.
DR   CD-CODE; 91857CE7; Nucleolus.
DR   EvolutionaryTrace; P22392; -.
DR   GeneWiki; NME1-NME2; -.
DR   GeneWiki; NME2; -.
DR   Pharos; P22392; Tbio.
DR   PRO; PR:P22392; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P22392; protein.
DR   Bgee; ENSG00000243678; Expressed in left ovary and 96 other cell types or tissues.
DR   ExpressionAtlas; P22392; baseline and differential.
DR   GO; GO:0071944; C:cell periphery; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0030027; C:lamellipodium; IDA:HGNC-UCL.
DR   GO; GO:0005634; C:nucleus; HDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0001726; C:ruffle; IDA:HGNC-UCL.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0120225; F:coenzyme A binding; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; IDA:UniProtKB.
DR   GO; GO:0001216; F:DNA-binding transcription activator activity; IDA:UniProtKB.
DR   GO; GO:0051880; F:G-quadruplex DNA binding; IDA:UniProtKB.
DR   GO; GO:0019003; F:GDP binding; IMP:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0016301; F:kinase activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004550; F:nucleoside diphosphate kinase activity; IDA:UniProtKB.
DR   GO; GO:0004673; F:protein histidine kinase activity; IDA:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; TAS:HGNC-UCL.
DR   GO; GO:0006241; P:CTP biosynthetic process; IEA:InterPro.
DR   GO; GO:0006183; P:GTP biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0046042; P:ITP biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:HGNC-UCL.
DR   GO; GO:0009142; P:nucleoside triphosphate biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:UniProtKB.
DR   GO; GO:2000144; P:positive regulation of DNA-templated transcription initiation; IDA:UniProtKB.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IMP:HGNC-UCL.
DR   GO; GO:0045618; P:positive regulation of keratinocyte differentiation; IMP:HGNC-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0045682; P:regulation of epidermis development; IMP:HGNC-UCL.
DR   GO; GO:0042304; P:regulation of fatty acid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006228; P:UTP biosynthetic process; IEA:InterPro.
DR   CDD; cd04413; NDPk_I; 1.
DR   FunFam; 3.30.70.141:FF:000015; Nucleoside diphosphate kinase B; 1.
DR   Gene3D; 3.30.70.141; Nucleoside diphosphate kinase-like domain; 1.
DR   HAMAP; MF_00451; NDP_kinase; 1.
DR   InterPro; IPR034907; NDK-like_dom.
DR   InterPro; IPR036850; NDK-like_dom_sf.
DR   InterPro; IPR001564; Nucleoside_diP_kinase.
DR   InterPro; IPR023005; Nucleoside_diP_kinase_AS.
DR   NCBIfam; NF001908; PRK00668.1; 1.
DR   PANTHER; PTHR11349; NUCLEOSIDE DIPHOSPHATE KINASE; 1.
DR   Pfam; PF00334; NDK; 1.
DR   PRINTS; PR01243; NUCDPKINASE.
DR   SMART; SM00562; NDK; 1.
DR   SUPFAM; SSF54919; Nucleoside diphosphate kinase, NDK; 1.
DR   PROSITE; PS00469; NDPK; 1.
DR   PROSITE; PS51374; NDPK_LIKE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Cell projection; Cytoplasm;
KW   Direct protein sequencing; DNA-binding; Kinase; Magnesium; Metal-binding;
KW   Nucleotide metabolism; Nucleus; Proteomics identification;
KW   Reference proteome; Transcription; Transcription regulation; Transferase.
FT   CHAIN           1..152
FT                   /note="Nucleoside diphosphate kinase B"
FT                   /id="PRO_0000137117"
FT   REGION          1..66
FT                   /note="Interaction with AKAP13"
FT                   /evidence="ECO:0000269|PubMed:15249197"
FT   ACT_SITE        118
FT                   /note="Pros-phosphohistidine intermediate"
FT                   /evidence="ECO:0000305|PubMed:16313181,
FT                   ECO:0000305|PubMed:1851158"
FT   BINDING         12
FT                   /ligand="DNA"
FT                   /ligand_id="ChEBI:CHEBI:16991"
FT                   /evidence="ECO:0000269|PubMed:19435876,
FT                   ECO:0007744|PDB:3BBB"
FT   BINDING         12
FT                   /ligand="GDP"
FT                   /ligand_id="ChEBI:CHEBI:58189"
FT                   /evidence="ECO:0000269|PubMed:19435876,
FT                   ECO:0000269|PubMed:8747457, ECO:0007744|PDB:1NUE,
FT                   ECO:0007744|PDB:3BBF"
FT   BINDING         52
FT                   /ligand="DNA"
FT                   /ligand_id="ChEBI:CHEBI:16991"
FT                   /evidence="ECO:0007744|PDB:3BBB"
FT   BINDING         88
FT                   /ligand="GDP"
FT                   /ligand_id="ChEBI:CHEBI:58189"
FT                   /evidence="ECO:0000269|PubMed:19435876,
FT                   ECO:0000269|PubMed:8747457, ECO:0007744|PDB:1NUE,
FT                   ECO:0007744|PDB:3BBF"
FT   BINDING         94
FT                   /ligand="DNA"
FT                   /ligand_id="ChEBI:CHEBI:16991"
FT                   /evidence="ECO:0000269|PubMed:19435876,
FT                   ECO:0007744|PDB:3BBB"
FT   BINDING         94
FT                   /ligand="GDP"
FT                   /ligand_id="ChEBI:CHEBI:58189"
FT                   /evidence="ECO:0000269|PubMed:19435876,
FT                   ECO:0000269|PubMed:8747457, ECO:0007744|PDB:1NUE,
FT                   ECO:0007744|PDB:3BBF"
FT   BINDING         115
FT                   /ligand="DNA"
FT                   /ligand_id="ChEBI:CHEBI:16991"
FT                   /evidence="ECO:0000269|PubMed:19435876,
FT                   ECO:0007744|PDB:3BBB"
FT   BINDING         115
FT                   /ligand="GDP"
FT                   /ligand_id="ChEBI:CHEBI:58189"
FT                   /evidence="ECO:0000269|PubMed:19435876,
FT                   ECO:0000269|PubMed:8747457, ECO:0007744|PDB:1NUE,
FT                   ECO:0007744|PDB:3BBF"
FT   BINDING         118
FT                   /ligand="DNA"
FT                   /ligand_id="ChEBI:CHEBI:16991"
FT                   /evidence="ECO:0000269|PubMed:19435876,
FT                   ECO:0007744|PDB:3BBB"
FT   BINDING         152
FT                   /ligand="GDP"
FT                   /ligand_id="ChEBI:CHEBI:58189"
FT                   /evidence="ECO:0000269|PubMed:19435876,
FT                   ECO:0000269|PubMed:8747457, ECO:0007744|PDB:1NUE,
FT                   ECO:0007744|PDB:3BBF"
FT   VAR_SEQ         1
FT                   /note="M -> MANCERTFIAIKPDGVQRGLVGEIIKRFEQKGFRLVGLKFMQASEDL
FT                   LKEHYVDLKDRPFFAGLVKYMHSGPVVAMVWEGLNVVKTGRVMLGETNPADSKPGTIRG
FT                   DFCIQVGRTM (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:16442775"
FT                   /id="VSP_036708"
FT   MUTAGEN         88
FT                   /note="R->A: Decreased single-stranded DNA-binding and
FT                   nucleotide-binding activity. No effect on 3D-structure."
FT                   /evidence="ECO:0000269|PubMed:19435876"
FT   MUTAGEN         118
FT                   /note="H->N: Loss of histidine kinase activity."
FT                   /evidence="ECO:0000269|PubMed:17157250"
FT   HELIX           2..4
FT                   /evidence="ECO:0007829|PDB:8PYW"
FT   STRAND          6..11
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   HELIX           13..17
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   HELIX           21..31
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   STRAND          34..41
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   HELIX           45..51
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   HELIX           53..55
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   HELIX           61..68
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   STRAND          73..80
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   HELIX           83..91
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   HELIX           96..98
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   HELIX           104..108
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   HELIX           112..114
FT                   /evidence="ECO:0007829|PDB:3BBC"
FT   STRAND          117..119
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   HELIX           123..133
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   HELIX           136..138
FT                   /evidence="ECO:0007829|PDB:3BBB"
FT   HELIX           147..150
FT                   /evidence="ECO:0007829|PDB:3BBB"
SQ   SEQUENCE   152 AA;  17298 MW;  1A5C3F84D7AD272C CRC64;
     MANLERTFIA IKPDGVQRGL VGEIIKRFEQ KGFRLVAMKF LRASEEHLKQ HYIDLKDRPF
     FPGLVKYMNS GPVVAMVWEG LNVVKTGRVM LGETNPADSK PGTIRGDFCI QVGRNIIHGS
     DSVKSAEKEI SLWFKPEELV DYKSCAHDWV YE
//
